DeepMed Research

FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-10-20

Last Posted Date: 2021-03-09

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT02939651

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Carcinoma Breast Stage IV

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2016-04-28

Last Posted Date: 2024-06-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 87

Registration Number: NCT02755272

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 3 locations

Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Intimacy Enhancing Intervention
Behavioral: Living Healthy Together
Behavioral: Partner-Assisted Coping Skills Training
Behavioral: Behavioral, Psychological or Informational Intervention

First Posted Date: 2016-03-29

Last Posted Date: 2018-10-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 89

Registration Number: NCT02721147

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma of the Bladder

Interventions: Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin
Drug: Cisplatin
Radiation: Intensity modulated radiation therapy (IMRT)
Procedure: Transurethral Resection of Bladder tumor
Drug: 5-FU
Drug: Mitomycin C

First Posted Date: 2016-03-17

Last Posted Date: 2024-12-24

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 78

Registration Number: NCT02710734

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Sidney kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States

and more 1 locations

Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

Phase 2

Terminated

Conditions: Laryngeal Neoplasms

Interventions: Radiation: IMRT Radiation

First Posted Date: 2015-12-17

Last Posted Date: 2021-03-09

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 2

Registration Number: NCT02633540

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1

Completed

Conditions: Cutaneous T-cell Lymphoma (CTCL)

Interventions: Drug: Romidepsin
Drug: Brentuximab vedotin

First Posted Date: 2015-11-30

Last Posted Date: 2025-04-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT02616965

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania, Perelman Center, Philadelphia, Pennsylvania, United States

Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: interferon-gamma and nivolumab

First Posted Date: 2015-11-25

Last Posted Date: 2019-11-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 26

Registration Number: NCT02614456

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients

Phase 2

Completed

Conditions: Cancer of Prostate

Interventions: Drug: Observation and Bicalutamide
Drug: Metformin and Bicalutamide

First Posted Date: 2015-11-25

Last Posted Date: 2022-03-29

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 29

Registration Number: NCT02614859

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Phase 1

Completed

Conditions: Advanced Solid Tumors
Multiple Myeloma

Interventions: Drug: ONC-201

First Posted Date: 2015-11-20

Last Posted Date: 2021-06-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 33

Registration Number: NCT02609230

Locations: 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Cervical Cancer Screening Intervention Among Korean American Women

Not Applicable

Completed

Conditions: Cervical Carcinoma

Interventions: Behavioral: Culturally appropriate intervention
Behavioral: General health education control

First Posted Date: 2015-11-03

Last Posted Date: 2021-01-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 744

Registration Number: NCT02594826

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy